14,020 AbbVie Inc. $ABBV Shares Acquired by Sapient Capital LLC

Sapient Capital LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 210,256 shares of the company’s stock after buying an additional 14,020 shares during the period. AbbVie comprises approximately 0.8% of Sapient Capital LLC’s investment portfolio, making the stock its 19th biggest position. Sapient Capital LLC’s holdings in AbbVie were worth $55,001,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Ranch Capital Advisors Inc. boosted its stake in shares of AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after purchasing an additional 4,017 shares during the period. Capital Advisors Inc. OK lifted its holdings in AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in AbbVie in the 2nd quarter valued at about $23,557,000. Wedge Capital Management L L P NC grew its stake in AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after acquiring an additional 9,380 shares in the last quarter. Finally, Mission Wealth Management LP increased its position in shares of AbbVie by 119.1% during the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after acquiring an additional 37,531 shares during the period. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

Analyst Upgrades and Downgrades

Several research analysts have commented on ABBV shares. Wells Fargo & Company raised their price objective on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. BMO Capital Markets increased their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Royal Bank Of Canada upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Finally, Leerink Partners increased their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.64.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

AbbVie Stock Up 0.3%

Shares of NYSE ABBV traded up $0.84 during mid-day trading on Thursday, reaching $272.20. 5,492,274 shares of the company were exchanged, compared to its average volume of 6,424,160. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94. The firm has a 50-day moving average of $258.56 and a 200 day moving average of $236.35. The stock has a market cap of $480.92 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.22 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts forecast that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.